GLP-1 Drug Access Set to Expand
Patent settlements may dramatically expand access to GLP-1 drugs like Ozempic reported, with telehealth platforms potentially offering them at reduced prices.
The settlement between Novo Nordisk and Hims & Hers allows the telehealth company to offer a compounded version of semaglutide, the active ingredient in Ozempic and Wegovy. This could lead to more affordable options for patients seeking these medications for weight management and diabetes. This expanded access could put pressure on other manufacturers to lower their prices or develop generic versions of GLP-1 drugs. For tech managers, this situation highlights the importance of understanding market dynamics and competitive pressures when making strategic decisions about product development and pricing. Telehealth platforms like Hims & Hers are disrupting traditional healthcare models by offering convenient and accessible solutions. As a software development manager, consider how these disruptive forces might impact your own industry and how you can leverage technology to create innovative solutions.
